Literature DB >> 11576949

Osteoprotegerin levels before and after renal transplantation.

T Sato1, Y Tominaga, Y Iwasaki, J J Kazama, T Shigematsu, H Inagaki, I Watanabe, A Katayama, T Haba, K Uchida, M Fukagawa.   

Abstract

Osteoprotegerin (OPG) is a newly identified glycoprotein that belongs to the tumor necrosis factor receptor superfamily and regulates bone mass by inhibiting osteoclastic bone resorption. The regulatory mechanism of OPG is still unclear after successful renal transplantation (RTX), however, resulting in resolution of uremia. The present study was designed to clarify the potential role of OPG in uremia and after RTX under immunosuppressive therapy. We evaluated circulating OPG levels by measuring them before and after RTX (postoperative days 2, 14, and 28). Our protocol of immunosuppressive drugs was dual therapy using cyclosporine and steroids. Serum OPG was quantitated using enzyme-linked immunosorbent assay. After successful RTX, serum OPG levels decreased significantly on day 14 and day 28 compared with the baseline level (P < 0.05). Creatinine clearance dramatically increased until day 14 and decreased thereafter. Serum OPG declines for the first 2 weeks after RTX owing to functioning allograft and decreases again for the next 2 weeks because of steroids and possible immunosuppressive agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576949     DOI: 10.1053/ajkd.2001.27437

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

1.  Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?

Authors:  K Kananen; L Volin; K Laitinen; T Ruutu; M J Välimäki
Journal:  Osteoporos Int       Date:  2005-12-31       Impact factor: 4.507

Review 2.  Osteoprotegerin and kidney disease.

Authors:  Alejandra Montañez-Barragán; Isaias Gómez-Barrera; Maria D Sanchez-Niño; Alvaro C Ucero; Liliana González-Espinoza; Alberto Ortiz
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

3.  Osteoprotegerin and bone mineral density in hemodialysis patients.

Authors:  A Nakashima; N Yorioka; S Doi; N Takasugi; K Shigemoto; N Kohno
Journal:  Osteoporos Int       Date:  2006-04-07       Impact factor: 4.507

4.  Serum Osteoprotegerin Levels Related With Cardiovascular Risk Factors in Chronic Kidney Disease.

Authors:  Pinar Demir; Fusun Erdenen; Hale Aral; Turker Emre; Sennur Kose; Esma Altunoglu; Anil Dolgun; Berrin Bercik Inal; Aydin Turkmen
Journal:  J Clin Lab Anal       Date:  2016-03-17       Impact factor: 2.352

5.  Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis.

Authors:  Constantinos Giaginis; Aikaterini Papadopouli; Athina Zira; Athanasios Katsargyris; Christos Klonaris; Stamatios Theocharis
Journal:  Med Sci Monit       Date:  2012-10

6.  Association between serum osteoprotegerin level and renal prognosis in nondialysis patients with chronic kidney disease in the Korean Cohort Study for Outcomes in Patients with Chronic Kidney Disease (the KNOW-CKD Study).

Authors:  Tae Ryom Oh; Chana Myeong; Su Hyun Song; Hong Sang Choi; Sang Heon Suh; Chang Seong Kim; Eun Hui Bae; Wookyung Chung; Kyu Hun Choi; Kook Hwan Oh; Seong Kwon Ma; Soo Wan Kim
Journal:  Kidney Res Clin Pract       Date:  2021-12-29

7.  Elevated Circulating Osteoprotegerin and Renal Dysfunction Predict 15-Year Cardiovascular and All-Cause Mortality: A Prospective Study of Elderly Women.

Authors:  Joshua R Lewis; Wai H Lim; Thor Ueland; Germaine Wong; Kun Zhu; Ee M Lim; Jens Bollerslev; Richard L Prince
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

8.  Osteoprotegerin inhibits calcification of vascular smooth muscle cell via down regulation of the Notch1-RBP-Jκ/Msx2 signaling pathway.

Authors:  Shaoqiong Zhou; Xin Fang; Xing Fang; Huaping Xin; Wei Li; Hongyu Qiu; Siming Guan
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.